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BB Wistar  rats  are  a  partially  inbred  line of rats prone to develop insulin- 
dependent diabetes mellitus (IDDM), l usually between 60 and 140 d of age (1- 
5).  The disease is characterized  by the sudden onset of severe hyperglycemia, 
glycosuria, and weight loss followed by death within a  few days unless insulin is 
administered.  Thus,  clinically,  this  disease  closely  resembles  human  insulin- 
dependent diabetes mellitus (type  1, or juvenile onset diabetes).  Histologically, 
BB rats show pancreatic mononuclear cell infiltrates (PMI) (also called pancreatic 
lymphocytic infiltrates [PLI]), which are found initially around ducts and acini 
(before the onset of diabetes) and eventually involve islets of Langerhans (insu- 
litis).  At this stage, there is severe beta cell destruction and hence, insulinopenia 
(5). By electron microscopy and/or immunohistochemical techniques these mono- 
nuclear cell  infiltrates can  be identified as  macrophages,  T  cells, and  B  cells. 
Occasionally, eosinophils are also present. 
In  our hands, approximately one in  three  BB rats  develops overt  diabetes. 
However, some rats remain normoglycemic despite the histological presence of 
PMI. Since BB rats are not completely inbred this heterogeneity in expression 
of disease  is  not  surprising.  We  are  presently  in  the  process  of developing 
congenic lines by crossing BB rats with other rat strains. Our studies at this time 
suggest that development of IDDM correlates strongly with three independently 
inherited characteristics:  (a) the major histocompatibility complex (MHC) hap- 
lotype RT1  (all  diabetic  rats  are  RT1 u homozygous or  heterozygous) (2);  (b) 
lymphopenia, affecting primarily T  cells (6,  7); and (c) PMI (6).  Only rats with 
all three of these characteristics become overtly diabetic. 
Several immune abnormalities have been described in BB rats. These rats have 
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reduced T  cell numbers and are susceptible to infections (3, 6-8). We and others 
(7) found a  decrease in the T  helper (Th,W3/25 +) to T  suppressor (T  s, OX8 ÷) 
ratios in BB rats. BB rats show reduced responses in mixed lymphocyte cultures 
(8), to concanavalin A (Con A), and to other T  cell mitogens (7, 9). Autoantibodies 
to islet cells, lymphocytes, and other autoantigens have been described (10,  11). 
Furthermore, BB rats frequently develop thyroiditis (12), and B cell lymphomas 
(13,  14). 
In this study we document deficient production of IL-2 by BB rat spleen cells 
in response to T  cell mitogens. We present evidence that this defect is not due 
to an  inability of macrophages to secrete  IL-1,  or to an inability of T  cells to 
produce IL-2. Instead, the defect in IL-2 production is largely a consequence of 
macrophage suppression.  Thus, the deficient production of IL-2 by BB spleen 
cells in  response  to Con  A  is  greatly improved by partial  depletion of macro- 
phages.  BB  spleen  cells  and  BB  splenic  macrophages  strongly  suppress  the 
response of Wistar Furth (WF; MHC matched normal control rat) spleen cells to 
Con A. The prostaglandin synthetase inhibitor indomethacin partially reverses 
the suppressive  effect of BB macrophages, while the enzyme catalase, and the 
tumor  promoter  phorbol  myristate acetate  have  no  effect.  Furthermore,  BB 
macrophages do not degrade IL-2. The possible significance of these findings to 
the disease complex of BB rats is discussed. 
Material and Methods 
Rats.  Male and female BB rats were supplied by Dr. P. Thibert, Department of Animal 
Resources, Department of Health and Welfare, Ottawa, Canada. These rats express the 
RT 1  u MHC haplotype. The genetic, endocrine, and histologic characteristics of these rats 
have been described elsewhere (1, 2, 4-6). The WF rats (RT 1  u) were bred and maintained 
in the McGill Cancer Centre animal colony. Rats used in this study ranged from 35 to 
115 d of age. 
Preparation of Cell Populations and Culture Conditions.  Splenectomies, accompanied by 
pancreatic biopsies, were performed under ether anesthesia and aseptic conditions. After 
surgery the rats were kept alive and observed for development of diabetes mellitus by 
daily testing for glucosuria. This surgical procedure does not change the incidence of 
diabetes in BB rats (unpublished observation). 
Cells  were  cultured  in  96-well,  flat-bottomed microtiter plates  (Linbro  76-032-05; 
McLean, VA) in medium consisting of RPMI 1640 supplemented by L-glutamine, 25 mM 
Hepes (Gibco Laboratories, Grand Island, NY), 50 #M 2-mercaptoethanol, penicillin (50 
U/ml)-streptomycin (50 #g/ml) mixtures (Flow Laboratories, McLean, VA), and 5% fetal 
calf serum (FCS) (lot 29101648,  Flow  Laboratories, Mississauga,  Ontario).  Cells were 
cultured in a humidified atmosphere at 37°C, in the presence of 5% CO~. 
In some experiments B cells were depleted by panning twice on anti-rat immunoglobulin 
(Ig) coated plates as described by Wysocki and Sato (15). Spleen cells were incubated on 
these plates at 4°C at a concentration of 107 cells/plate for 90 min. Recovered unbound 
cells consisted of <5% B cells as determined by immunofluorescence. 
T  cells were depleted by treating spleen cells with biotin-conjugated W3/I 3 (Sera-lab, 
MAS 010C, a pan anti-T cell monoclonal antibody), followed by panning twice on avidin- 
coated plates as described by Basch et al. (I 6). <5% of nonadherent cells were W3/13 + as 
determined by immunofluorescence. T-depleted populations failed to respond to concan- 
avalin A (Con A). 
Macrophages were  depleted by passing spleen  cells  on  Sephadex  G-10  columns as 
described by Ly and Mishell (17). BB rat spleen cells consisted of 5-8% macrophages as 
determined by uptake of fluorescent microbeads (Polysciences  Inc., Warrington, PA). 
Following passage on Sephadex G- 10, < 1% of the cells could be identified as macrophages PRUD'HOMME  ET  AL.  465 
by this method. 
In some experiments macrophages were enriched on the basis of cell density (18) and 
adherence in a two-step producedure. First, in order to deplete T  cells, spleen cells were 
fractionated on a discontinuous Percoll (Pharmacia, Uppsala, Sweden) density gradient, 
consisting of three densities:  1.085,  1.052, and 1.030 g/ml. Spleen cells were layered on 
top of the gradient (at 4°C) and spun at 400 g for 30 min. 
Fraction 1 at the 1.030/1.052 interphase consisted of 25-40% macrophages (by uptake 
of microbeads), 60-70% B lymphocytes, and <5% T cells. Fraction 1 cells failed completely 
to respond to Con A. Fraction 2 (1.052/1.085 ~nterphase) comprised almost all splenic T 
cells (with 25-40% B cells, and 2-3%-macrophages) and generated high responses to Con 
A. 
T  cell-depleted fraction 1 was further enriched for macrophages on the basis of cell 
adherence. Fraction 1 cells were added in various numbers to the wells of 96-well plates 
and incubated at 37°C for 4  h.  Nonadherent cells were removed by vigorous flushing 
with medium using a pasteur pipette (three washes). Macrophage numbers were estimated 
by the number of adherent cells per high power field (hpf, 40× objective). 
MitogeJ~ Assays.  Stimulation  of spleen  cells  with  T  cell-dependent  mitogens  were 
performed at cell densities ranging from 105 to 5 ×  105 cells/250 #1. Mitogen doses were 
5 ttg/ml for Con A (Sigma C-2010; Sigma Chemical Co., St. Louis, MO),  1/30 dilution 
for phytohemagglutinin (PHA; Difco Laboratories, Detroit, MI), and  1 ttg/ml for poke- 
weed mitogen (PWM, Sigma L-9379). [SH]Thymidine uptake was measured after 3 d of 
culture (18-h incubation with 1 ttCi [SH]thymidine per well), unless otherwise indicated. 
In some experiments indomethacin (Sigma 1-7378)  10 ug/ml, prostaglandin E1 and E2 
(PGE1  and PGE2 respectively, Sigma P-5515 and P-5640), catalase (Sigma C-100),  or 
phorbol myristate acetate (PMA, Sigma P8139) were added to the cultures. 
Interleukin  2 (IL-2) Assay.  The IL-2 assay was performed as described by Gillis et al. 
(19)  using  the  CTLL-2  cell  line  (a  kind  gift  from  Dr.  H.  Rode,  McGill  University, 
Montreal, Canada). Briefly, 104 CTLL-2 cells per well were cultured with various dilutions 
of Con A supernatants of spleen cells. [3H]Thymidine uptake was measured after 24 h of 
culture, following a 4-h incubation with 1 uCi [SH]thymidine per well.  1 U of IL-2 per ml 
was defined as that quantity of IL-2 producing one-half of maximal stimulation of CTLL- 
2. Test supernatants were compared to a standard IL-2 preparation. 
Incubation oflL-2 with Macrophages.  Con A supernatant (CAS) was used as a source of 
I L-2. CAS was added to graded numbers of macrophages (prepared as described above) 
in 96-well plates, and incubated at 37°C for 24 h in the presence or absence of 20 mg/ml 
a-methyI-D-mannoside (MM, Sigma M-6882). Supernatants were then recovered, passed 
through 0.2-#m filters, and stored at -20°C until used. 
h~terleuhin  1 (IL-I) Assay.  IL-1  was  measured by the mouse thymocyte proliferation 
assay, as described by Mizel (20). Briefly, supernatants derived from spleen cells cultured 
with or without 25 ug/ml of LPS (E.  coil 026:B6,  Difco Laboratories,), for 48  h  were 
added  at  various dilutions  to  10  n BALB/c mouse  thymocytes/250 /zl. [SH]Thymidine 
uptake  by the  thymocytes was  determined after an  18-h  incubation with  1 ttCi  [3H]- 
thymidine/well on day 3 of culture. 
Results 
Respo~lse of BB Splee~ Cells to T-depe~ldent Mitogens.  The proliferative responses 
of BB rat spleen cells to Con A, PHA, and PWM were very low when compared 
with  MHC-matched normal control WF rats  (Fig.  1).  In  fact, addition  of these 
mitogens  to  BB  spleen  cells  yielded counts  lower  than  with  medium  alone  in 
several BB rats (hence a  negative Acpm). 
IL-2  Production  by  BB  Spleen  Cells.  The  mean  IL-2  levels  of  24-h  Con  A 
supernatants of BB spleen cells (5 ×  105 cells/well) were approximately eightfold 
lower than those of WF controls (Fig. 2) (p <  0.001 by the Student's t-test). Only 
2 out of 10 BB rats tested bad  IL-2 levels above  10 U/ml, while WF IL-2 levels 466  IMMUNE  DYSFUNCTION  IN  BB  RATS 
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FIGURE  1.  Proliferative responses of BB and  WF  spleen  cells to  T-dependent  mitogens. 
Acpm =  [3H]thymidine uptake of spleen cells with mitogens -  [SH]thymidine uptake of spleen 
cells with medium alone. Acpm was measured on day 3 of culture. Con A =  5 #g/ml, PHA = 
1/30 dilution, PWM  =  1 #g/ml. O, rats that showed no clinical evidence of diabetes for at 
least 3 months following assay; I-I, rats tested before the onset of IDDM; A, rats with IDDM at 
time of assay. Horizontal bars represent the mean values for BB and WF rats in each assay. 
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FIGURE  2.  Con A-induced IL-2 production (U/ml) in BB and WF spleen cells. 24-h Con A 
(5 pg/ml) supernatants from 5 X  105 spleen cells/250/z] were tested for IL-2 in the CTLL-2 
proliferation assay. @, t-I, A, see legend to Fig.  1. Vertical bars represent the mean values for 
BB and WF rats. 
ranged  from  64  to  144  U/ml.  However,  there  was  no  apparent  correlation 
between the clinical status of BB rats, or the subsequent development of IDDM, 
and IL-2 levels. Low IL-2 production appears to be a feature of all BB rats. 
Suppressive  Effects of BB Spleen  Cells on  WF Spleen  Cells.  The addition  of BB 
spleen cells to WF spleen cells resulted in a marked suppression of proliferation 
in  response  to  T  cell-dependent  mitogens  (Figs.  3  and  4),  while  addition  of 
similar numbers of WF spleen cells instead of BB cells, resulted in an increase in 
Acpm,  rather  than  suppression  (data  not  shown).  The  suppressive  effect was 
equally apparent on IL-2 secretion in response to Con A (Table I). The level of 
suppression varied among BB rats but was always present.  Less than  I  BB spleen 
cell  per  10  WF  spleen  cells  was  sufficient  to  generate  suppression  of both 
proliferation and IL-2 production (Fig. 5 and Table I). 
Cell Population  Responsible for Suppression.  T  cell depletion or B cell depletion 
had  no effect on  the  level of suppression  exerted by BB spleen  cells.  On  the PRUD'HOMME  ET  AL.  467 
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FIGURE 3.  Suppression of WF proliferative responses to T-dependent mitogens by BB spleen 
5  5  cells.  1.25 x  10  BB spleen cells were added to 1.25 x  10  WF spleen cells and mitogens on 
day 0. [3H]Thymidine uptake was measured on day 3 of assay. 
% suppression  =  Acpm WF -  (Acpm WF +  BB) x  100. 
Acpm WF 
Addition of WF spleen cells instead of BB resulted in approximate doubling of Acpm rather 
than suppression (not shown). O, D, A, and mitogen doses, see legend to Fig. 1. 
other hand, macrophage depletion by passage of spleen cells on Sephadex G-10 
completely abrogated the suppressive effects of BB cells (Fig. 4). In fact, following 
macrophage depletion, enhancement of responses rather than suppression was 
observed. This effect was seen in both diabetic and nondiabetic BB rats.  Fur- 
thermore, macrophage depletion greatly increased proliferation and IL-2 pro- 
duction of BB cells in response to Con A  (Table II).  It should be added that 
macrophages were not completely depleted by passage on Sephadex G-10 (see 
Materials and Methods). 
That macrophages were indeed the suppressor cell population (rather than 
some other adherent cell population) was further demonstrated by adding WF 
spleen cells to various numbers of BB splenic macrophages. Such macrophages 
were  isolated  on  the  basis  of both  cell  density (on  a  Percoll  gradient)  and 
adherence and contained <5% contaminating T  cells (see Materials and Meth- 
ods). BB macrophages in small numbers (150-250  adherent cells per  10  high 
power fields) suppressed WF proliferative responses to Con A by >90%, and IL- 
2 production by >80% (Table III). Adherent cells derived from whole BB spleen 
cell populations (omitting the density gradient step) had a closely similar effect 
ruling out an effect of Percoll in this assay (data not shown). WF-derived splenic 468  IMMUNE  DYSFUNCTION  IN  BB  RATS 
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proliferation.  1.25  x  105  BB  spleen  cells (with  or  without T  cell,  B  cell,  or  macrophage 
depletion) were added to  1.25  x  105 WF spleen cells and Con A  (5 #g/ml) on day 0.  [3l-I]- 
Thymidine uptake was measured on day  3  of assay.  Results of a  representative experiment 
with a diabetic, and a nondiabetic BB rat are shown. 
TABLE  I 
Suppressive Effect of BB Spleen Cells on IL-2 Production by WF Spleen 
Cells 
No. of BB spleen cells added to WF cells* 
IL-2 (% suppression)* 
Con A +  in- 
Con A ~  dometha- 
cinlg 
--  0  0 
104  50%  29% 
2.5 X  104  44%  29% 
7.5 X 104  79%  25% 
1.25 X I05  84%  41% 
1.25 X 10  s (macrophage depleted)  0% I  0% ! 
* 1.25 x  103 WF spleen cells per 250 #1. 
~: % suppression of IL-2 production = 
WF IL-2 production (U/ml) 
-  [WF +  BB 1L-2  Production (U/ml)] ×  100. 
WF IL-2 production (U/ml) 
IL-2 was determined in 24-h culture supernatants. Results of a  repre- 
sentative experiment are shown. 
5 ttg/ml Con A, 10 #g]ml indomethacin. 
I Negative values reflect enhancement rather than suppression. PRUD'HOMME  ET  AL. 
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FIGURE 5.  Effect of indomethacin on the suppressive effect of BB spleen cells on WF spleen 
cells. Graded doses of BB spleen cells were added to 1.25 x  105 WF spleen cells and Con A (5 
vg/ml) on day 0, with (A), or without (O) indomethacin (10 pg/ml). % suppression, see legend 
to Fig. 3. Results of a representative experiments are shown. 
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TABLE  I1 
Effect of Macrophage Depletion  and Indomethacin on Con A-induced Proliferation  and IL-2 
Production 
Strain 
Proliferation (Acpm X I 0 -s)  IL-2 (U/ml) 
Spleen cell  Macro- 
Con A +  no. (x  phage de-  Con A +  indo- 
10  -s)  pletion  Con A*  methacin*  Con A  indometh- 
acin 
BB 
WF 
1  -  -14.0  -11.3  3  6 
2.5  -  -16.1  -11.9  4  10 
2.5  +  148.5  146.8  46  32 
5  -  -1.2  0.4  4  38 
1  -  234.5  207.8  32  36 
2.5  -  357.9  352.5  33  30 
5  -  384.8  348.2  76  76 
* Proliferation determined on day  3 of culture.  Negative values reflect lower counts with Con A 
than  with  medium  alone.  IL-2  levels  determined in  24-h  culture  supernatants.  Results  of a 
representative experiment are shown. 
* 5 pg/ml Con A, 10 #g/ml indomethacin. 470  IMMUNE DYSFUNCTION IN  BB RATS 
TABLE  III 
BB Macrophages Suppress Con A-induced Responses 
WF Spleen cells* + Con A 
Macrophage* no. (per 
10 hpf)  Proliferation (Acpm × 
10 s)  IL-2 (U/ml) 
0  238 (0%)  ~  28 
30-50  106 (55%)  11 
150-250  17 (93%)  5 
* Macrophages were isolated on the basis of both cell density (Percoll 
gradient) and adherence. 
* 2.5 × l0  b WF spleen cells per well. Results represent the mean of the 
effect of macrophages from three BB rats on WF spleen cells. 
Numbers in parentheses represent % suppression (see legend to Fig. 3). 
macrophages did not suppress in this assay in the cells doses shown in Table III. 
However,  much larger numbers of WF splenic  macrophages (800-1,200  mac- 
rophages per  10 high power fields) could suppress WF responses to Con A  by 
~50% (not shown). Thus even normal spleens contain a population of suppressor 
macrophages which, however, are clearly more numerous in BB spleens than in 
normal spleens. 
Effect  of lndomethacin  and  Catalase  on  the Suppressive  Effect  of BB Spleen  Cells. 
Indomethacin was effective in reducing partial suppression of proliferation (50% 
or  less)  by  BB  cells of WF  cells,  but  had  less  effect in  situations of complete 
suppression (Fig. 5). Comparatively, indomethacin was more effective in reducing 
severe suppression of IL-2 production than reducing severe suppression of Con 
A-induced proliferation (Table  I  and Fig.  5).  While indomethacin did little to 
increase proliferation of unfractionated BB spleen cells regardless of cell density 
in culture (105 to 5 x  105 cells/well), it nevertheless caused a marked increase in 
I L-2 production (Table I I) in high cell density cultures (5 x  105 cells/well), while 
having little or no effect on WF responses. 
On the other hand, addition of the enzyme catalase to cultures in amounts as 
high as  15,000  U/ml had no effect on BB spleen cells responses to Con A.  In 
addition, catalase did not alter the effect of indomethacin (data not shown).  It 
thus seems unlikely that the suppressive effect of BB macrophages is mediated 
by hydrogen peroxide generation. 
Suppression  of lL-2 Production  by PGEI and PGE2.  The suppressive effects of 
PGE1  and PGE2 on mitogen-induced responses in humans and mice have been 
documented by other authors (21-24).  As can be seen from Fig. 6, both PGE1 
and PGE2 can suppress Con A-induced proliferation and IL-2 production in rat 
cells. Physiological concentrations of PGE1 and PGE2 (1-10 ng/ml) caused 40- 
50% suppression of Con A-driven responses. PGE1 and PGE2 in doses ranging 
from  1 to  1,000  ng/ml did not affect the response of CTLL-2 cells to IL-2, in 
the IL-2 assay, and thus did not interfere with IL-2 determinations in prosta- 
glandin-containing supernatants (data not shown). 
BB Mac~vphages Do Not Inactivate IL-2.  No loss of IL-2 activity was found when 
IL-2 (from Con A  supernatants)  was incubated for  24  h  with macrophages in 
numbers up to 800-1,200  macrophages per  10 hpf (Table  IV). Similar results 
were obtained in  the presence  or absence  of the Con A  inhibitor a-methyl-o- PRUD'HOMME  ET  AL.  471 
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FIGURE 6.  The effect of POE1 and PGE2 on Con A-induced proliferation and IL-2 produc- 
tion in  WF  rats.  2.5  ×  105 WF spleen cells were cultured with Con  A  (5 #g/ml),  with or 
without PGE1 and PGE2. IL-2 levels were determined in 24-hour Con A supernatants, while 
proliferation ([SH]thymidine uptake) was measured on day 2  of assay.  Results represent the 
mean _.+ 1 SD of three WF spleens. O, PGE1; I,  PGE2. 
TABLE  IV 
BB Macrophages Do Not Inactivate IL-2 
Macrophage no. (per 10 hpf)  MM* (20 mg/ml)  IL-2* (U/ml) 
0  +  34 
-  33 
30-50  +  33 
-  35 
150-250  +  36 
-  34 
800-1,200  +  33 
-  35 
* MM, a-methyl-D-mannoside. 
* IL-2 from rat Con A  supernatant was incubated for 24 h  with macro- 
phages  with  or  without  MM.  Results  represent  the  mean  effect  of 
macrophages from three experiments on an IL-2 preparation. 
mannoside, ruling out IL-2 production by possible residual T  cells. Since such 
macrophage numbers had profound suppressive effects on IL-2 production these 
results rule out macrophage-mediated IL-2 inactivation as a suppressive mecha- 
nism. 
IL-I Production  by BB Spleen  Cells.  The secretion of IL-I, as determined by 
the thymocyte proliferation assay, was as high in BB rats as in WF rats (Table 
V).  This  occurred despite the fact that  the WF  control rats tested produced 
levels of IL-2 severalfold higher than the BB rats. The addition of indomethacin 472  IMMUNE  DYSFUNCTION  IN  BB  RATS 
TABLE  V 
IL-I Production  in BB and WF Rats 
Treatment of spleen cells 
IL-1  (cpm at l/s dilution)* 
BB*  WF  ~ 
Medium  2,401  +  887  1,813 +  303 
LPS  ~  6,342 +  853  6,310 +  1,781 
LPS +  indomethacin  0  8,106 +- 315  6,667 _+ 573 
* 106  mouse  thymocytes cultured  for  3  d  with  supernatants.  Results 
represent mean [SH]thymidine uptake  of three spleen +  1 SD.  Back- 
ground proliferation of thymocytes =  1,358 +  925; and thymocytes + 
LPS -- 2,846  +  735.  No difference was seen between BB and WF at 
lower or higher dilutions of IL-1. 
* Con A-induced IL-2 secretion for the rats tested in this experiment was 
5 +  1 U/ml for BB, and 105  +  28 U/ml for WF spleen cells. 
0 25 #g/ml LPS, and 10 t~g/ml indomethacin. Indomethacin alone did not 
stimulate proliferation of thymocytes (not shown). 
to spleen cells often resulted in apparent  increases in IL-1.  However, it should 
be remembered that indomethacin  will reduce the prostaglandin  concentration 
of such supernatants.  Prostaglandins  interfere with thymocyte proliferation (20) 
since this process depends on a  IL-1  ~  thymocyte ~  IL-2 sequence of events, 
and prostaglandins E1 and E2 inhibit IL-2 secretion. 
The addition to Con A-stimulated BB spleen cells of PMA in amounts ranging 
from 1 to 100 ng/ml did not improve proliferation or IL-2 production (data not 
shown). Since PMA is thought to act directly on T  cells and to reduce the need 
for IL-1  in T  cell activation  (25),  it seems unlikely that low IL-2 production in 
BB rats is secondary to an inability ofT cells to respond to IL-1. 
Discussion 
The BB rat represents one of the few animal  models available for study that 
spontaneously develops IDDM  (26).  The autoimmune  nature  of the disease is 
supported by the findings of insulitis (1), the presence of anti-islet cell antibodies 
in  the  sera  of the  animals  (11),  the  possibility  of preventing  the  disease  by 
immunosuppressive treatment (27), the strict association of the disease with the 
MHC RT1 u haplotype (2), and T  cell lymphopenia (6). Studies showing a lower 
incidence of disease in neonatally thymectomized BB rats (28), and in rats treated 
in  vivo with  anti-lymphocyte  antibodies  (27)  suggest an  important  role  for  T 
cells. 
Paradoxically, BB rats are immune deficient, have low T  cell numbers in blood 
and lymphoid organs (8), and respond poorly to T  cell mitogens (7). In this study 
we document  low production  of IL-2  in  BB rats  following stimulation  of BB 
spleen cells with Con A. Such a deficiency could be explained on the basis of T 
cell depletion,  or changes in the Th/Ts ratio in BB rats.  We find (unpublished 
observation), as have others (7, 8), that BB spleen cells consist of approximately 
half as many T  cells (percentage  of total cells) as non-diabetes-prone  controls, 
with a  decrease in Th/Ts ratios.  The findings in this study clearly indicate that 
alterations in T  cell numbers can account for only part of the decrease in IL-2 
production. Addition of spleen cells from BB rats (both diabetic and nondiabetic) PRUD'HOMME  ET  AL.  473 
to  WF  spleen  cells  strongly suppresses  the proliferative responses  to  Con  A, 
PWM,  and  PHA,  as  well  as  IL-2  production.  This  indicates  that  an  active 
suppressive process is at work. Depletion of T  cell or B cells from BB spleen cells 
had little effect on  this  suppressive  process.  On  the other hand,  macrophage 
depletion by passage through a Sephadex-G10 column completely abrogated the 
suppressive effect of BB spleen cells on the response of WF spleen cells to Con 
A. Furthermore, macrophage depletion greatly increased both proliferation and 
IL-2  production  by  BB  cells in  response  to  Con  A.  BB  splenic  macrophages 
(isolated on the basis of both cell density on Percoll gradients, and adherence) 
strongly suppressed WF spleen cells responses to Con A. Small numbers of BB 
macrophages were suppressive in this assay. On the other hand,  up to  10-fold 
greater numbers of WF  macrophages were necessary to obtain  an equivalent 
degree of suppression. These results indicate that suppressor macrophages can 
be found even in normal spleens, however, this cell population is greatly increased 
in BB rats. 
Although macrophage-mediated suppression is a well-known phenomenon, the 
mechanisms of suppression remain poorly understood. Metzger et al. (21) suggest 
that  this  phenomenon is  mediated by  activated macrophages.  These  authors 
found  that  following activation  with  thioglycollate,  or  C.  parvum, peritoneal 
macrophages acquired  the ability to  suppress  the  response of lymphocytes to 
mitogens. This response could be partially reversed by a prostaglandin synthetase 
inhibitor (indomethacin), or catalase. They postulated that macrophage activa- 
tion results in the production of prostaglandins and H202,  both of which suppress 
lymphocyte responses.  On  the other hand,  some authors believe that  soluble 
protein mediators play an important role in macrophage-mediated suppression 
(22). We find that indomethacin partially reverses the suppressive effects of BB 
spleen  cells,  while  catalase  has  no  effect.  Indomethacin  also  improves  IL-2 
production by unfractionated Con A-stimulated BB spleen cells. Furthermore, 
we find that the addition of PGE1  or PGE2 at physiological doses (1-10 ng/ml) 
to WF spleen cells suppresses Con A-induced proliferation and IL-2 production 
by  ~50%.  Clearly,  PGE1  and  PGE2  can  strongly suppress  T  cell  responses; 
however, other mediators are probably also involved in producing the marked 
suppressive effect (>90%)  of BB  macrophages.  Interestingly, we find that  BB 
macrophages have  a  strong  cytostatic effect on  tumor  cells,  2 and can  inhibit 
insulin  secretion by a  rat  insulinoma cell line.  This provides further evidence 
that BB rat spleens contain an unusually high number of activated macrophages. 
Other possible mechanisms to explain macrophage suppression in BB rats have 
been considered in this study. BB splenic macrophages secrete normal levels of 
IL-1,  and  do  not  inactivate  IL-2.  We  tested  the  effect of PMA  in  Con  A- 
stimulated cultures, since this substance has a direct effect on T  cells and reduces 
or abolishes the need for IL-1  in T  cell activation (25). However, PMA did not 
improve IL-2  production  by BB Con  A-stimulated spleen cells.  It thus seems 
unlikely that low IL-2 secretion is due to an inability of BB T  cells to respond to 
IL-1.  Interestingly, PMA improves IL-2  secretion in some lupus-prone mouse 
strains (29). 
2 Prud'homme,  G. J.,  A.  Fuks,  E.  Colle,  R.  D.  Guttmann.  1983.  Cytostatic  effects of splenic 
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The finding of excessive macrophage-mediated suppression is not unique to 
BB rats. "Suppressor" macrophages have been described in rheumatoid arthritis 
(30) and Hodgkin's disease (31), as well as in human (32, 33) and murine (34) 
systemic lupus  erythematosus (SLE,  a  systemic autoimmune disease).  In  fact, 
Gershwin et al. (34) demonstrated that the acquired Th deficiency of older SLE- 
prone (NZB×NZW)FI mice is secondary to the presence of splenic macrophage 
suppressor cells, and is unrelated to the premature degeneration or involution 
of thymus or thymic epithelial elements in these mice. These findings are similar 
to our findings in autoimmune BB rats. 
Interestingly, SLE, like IDDM in BB rats, is characterized by low IL-2 produc- 
tion (35-38), and other T  cell defects (39, 40).  Furthermore, a high incidence 
of lymphocytic infiltrates in  the pancreas of NZB (80%  incidence) and  MRL 
(50%  incidence) SLE-prone  mice has  been  reported  (41),  as  well  as,  a  high 
incidence  of  diabetes  in  encephaiomyocarditis  virus-infected  NZB,  and 
(NZB×NZW)F1  mice (42).  BB rats and some autoimmune mice thus share the 
phenomenon of PMI, although only BB rats spontaneously develop IDDM. 
The association of low IL-2  production, and other T  cell deficiencies, with 
autoimmune diseases has been difficult to explain. In fact, it is not clear that low 
IL-2 production contributes to the polyclonal B cell activation found in SLE (43, 
44), or to the occurrence of IDDM  in  BB rats.  However, by crossing BB rats 
with other rat strains (e.g. Buffalo) we found that only animals with deficient T 
cell function developed IDDM (6).  All diabetic offsprings of such crosses tested 
were found to be low producers of IL-2 (unpublished observation).  It is clear 
that although deficient T  cell function by itself does not cause IDDM in rats, this 
feature is nevertheless invariably associated with the disease. Expression of the 
disease only occurs if the RT1 u haplotype, and other yet poorly characterized 
genetic factors are also present (2, 6). 
The mechanism of macrophage activation in the BB rat has not been deter- 
mined in this study. In experimental systems the signals that can activate mac- 
rophages are  numerous and  include microbial antigens,  mitogens,  and  many 
chemicals, as well as iymphokines (22, 45-47). Studies are in progress to evaluate 
the possible presence of immune complexes or increased levels of interferon in 
the serum of BB rats.  Conceivably, antigen-specific Ia-restricted T  ceil-macro- 
phage interactions to a  putative islet cell antigen could lead to both T  cell and 
macrophage activation with secretion of monokines (e.g. IL-1) and lymphokines 
(e.g. IL-2, and ~,-interferon); as well as, a whole battery of vasoactive, chemotactic, 
and cytotoxic products by macrophages. This model is supported by the promi- 
nent presence of both macrophages and T  cells in islets of Langerhans during 
the acute phase of the disease. 
Finally, the finding that indomethacin can increase in vitro IL-2 secretion in 
BB rats suggests that prostaglandin  synthetase inhibitors may have useful im- 
munopotentiating effects in diseases characterized by low IL-2 production. 
Summary 
Spleen cells of diabetes-prone BB Wistar rats were found to generate exces- 
sively low proliferative responses, and interleukin 2 (IL-2) levels in response to 
T-dependent mitogens. This abnormality was not due solely to abnormal T  cell PRUD'HOMME  ET  AL.  475 
numbers  since:  (a)  addition  of BB spleen  cells or  BB splenic  macrophages  to 
normal  major  histocompatibility  complex  (MHC)-matched  Wistar  Furth  (WF) 
spleen cells resulted in severe suppression of concanavalin A (Con A)-, phytohe- 
magglutinin (PHA)-, and pokeweed mitogen (PWM)-mediated proliferation, and 
IL-2 production; (b) macrophage depletion from BB spleen cells, but not B cell 
or T  cell depletion,  removed completely the suppressive effects of BB cells on 
WF cells; (c) macrophage  depletion  greatly enhanced  the  response of BB lym- 
phocytes to  T-dependent  mitogens.  Although  suppressor  macrophages  could 
also be found in the spleen of WF control rats they were present in much smaller 
numbers than in the spleen of BB rats. The suppressive effect of BB macrophages 
was  partially  reduced  by  addition  of  the  prostaglandin  synthetase  inhibitor 
indomethacin to cultures. Furthermore, indomethacin (but not catalase or PMA) 
considerably augmented IL-2 secretion of Con A-stimulated BB spleen cells, but 
had little effect on WF spleen cells. In contrast, prostaglandins E1 and E2 (PGE1 
and  PGE2)  suppressed  IL-2  production.  While  IL-2  secretion  was  severely 
depressed in BB rats, unstimulated and lipopolysaccharide (LPS)-stimulated IL- 
l  secretion by splenic macrophages was normal.  BB macrophages did not inac- 
tivate  IL-2.  Low IL-2 production  and  macrophage-mediated  suppression  were 
features of all BB rats tested. 
Received for publication 29 August 1983 and in revised  form 28 October 1983. 
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